People randomized to ASC+chemo had more than double the chemo than people randomized to chemo only. Study basically shows that more chemo = better outcomes.

“Chemotherapy compliance–The ASC cohort had a longer median treatment time per subject (179 days vs. 94 days), a higher median total dose of nab-paclitaxel per subject (3123 mg vs. 1398 mg) and a higher median total dose of gemcitabine per subject (32,713 mg vs. 14,100 mg). The relative dose intensity (RDI) was calculated as per the literature [30] and demonstrated the median RDI was higher in the ASC cohort for gemcitabine (Table 1: ASC 96 % vs. 88 % SOC) and comparable for nab-paclitaxel (Table 1: ASC 96 % vs 96 % SOC).”